LEEEF Leef Brands Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1711141 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin42.1%
Operating margin-16.3%
Net margin-38.2%
FCF margin-23.4%
EBITDA margin-12.3%
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets92.5%
Debt / equity0.00x
Current ratio2.24x
Interest coverage-3.95x
Cash quality & payout
Operating cash flow / net income0.40x
Accruals ratio—
Payout ratio—
Capex / revenue8.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $34.79M | $28.50M |
| Cost of revenue | $24.30M | $20.81M |
| Gross profit | $10.48M | $7.68M |
| R&D expense | $19,696 | $18,983 |
| SG&A expense | $3.12M | $2.40M |
| Operating income | -$7.59M | -$7.99M |
| Interest expense | $2.37M | $5.16M |
| Pretax income | -$15.11M | -$21.31M |
| Income tax | $2.52M | $3.31M |
| Net income | -$17.63M | -$24.62M |
| EBITDA | -$6.33M | -$6.94M |
| EPS (basic) | -0.10 | -0.17 |
| EPS (diluted) | -0.10 | -0.17 |
| Weighted avg. shares (diluted) | 184.91M | 142.60M |
| Balance sheet | ||
| Cash & equivalents | $2.19M | $2.73M |
| Receivables | $1.59M | $2.39M |
| Inventory | $3.35M | $4.22M |
| Current assets | $8.15M | $10.48M |
| PP&E, net | $25.04M | $26.04M |
| Goodwill | $0 | $0 |
| Intangibles | $1.12M | $2.23M |
| Total assets | $36.40M | $42.98M |
| Current liabilities | $8.35M | $11.41M |
| Total liabilities | $44.67M | $55.41M |
| Shareholders' equity | -$8.27M | -$12.43M |
| Shares outstanding | 257.95M | 172.98M |
| Cash flow statement | ||
| Operating cash flow | -$336,895 | -$1.05M |
| Capital expenditure | $642,014 | $5.92M |
| Free cash flow | -$978,909 | -$6.97M |
| Investing cash flow | -$749,223 | -$6.27M |
| Financing cash flow | $545,204 | $3.63M |
| Depreciation & amortization | $1.26M | $1.04M |
| Stock-based compensation | $2.69M | $1.30M |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.